XPO1 and melanoma: Overexpression of CRM1 has been found in a range of cancers from cancers of epithelial/mesenchymal origin such as ovarian, breast, esophageal, prostate, neuroblastoma, lung, gastric, colorectal, melanoma and thyroid to hematologic malignancies such as T-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, or AML, and increased CRM1 expression leads to a worse prognosis in a number of cancers [1–3, 7, 21, 23, 24, 26–28, 59, 127–131].